Gilead Sciences (GILD) Net Margin (2009 - 2026)
Gilead Sciences' (GILD) quarterly Net Margin came in at 134.51% in Q2 2026, down 16220.0% on a YoY basis from N/an in Q2 2025, and down 563.24% quarter-over-quarter from 29.04% in Q1 2026.
Powered by 
Analysis
Gilead Sciences (GILD) Net Margin (2009 - 2026) Analysis & Trends
Gilead Sciences (GILD) has reported Net Margin for 18 consecutive years, with 134.51% the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Net Margin fell 16220.0% year-over-year to 134.51%; the trailing twelve-month figure through Jun 2026 stood at 9.51% (down 3137.0% YoY), and the FY2025 full-year result was 28.9%, up 2724.0% from the prior year.
- Net Margin retreated to 134.51% in Q2 2026 per GILD's latest filing, from 29.04% in the prior quarter.
- Across five years, Net Margin topped out at 39.28% in Q3 2025 and bottomed at 134.51% in Q2 2026.
- Historically, Net Margin has averaged 8.99% across 5 years, with a median of 21.0% in 2022.
- The sharpest annual moves came in 2025 and 2026: Net Margin surged 8211 bps in 2025, then plunged 16220 bps in 2026.
- Over 5 years, Net Margin stood at 22.1% in 2022, then declined by 10 bps to 19.9% in 2023, then grew by 18 bps to 23.54% in 2024, then jumped by 35 bps to 31.9% in 2025, then plunged by 522 bps to 134.51% in 2026.
- According to Business Quant data, Net Margin over the past three periods registered 134.51%, 29.04%, and 31.9% for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 207.17 Bn | 193.18 Bn | 7.24 Bn | 23.62% |
| 2 | Gilead Sciences | 179.52 Bn | 176.34 Bn | 6.22 Bn | -134.51% |
| 3 | Vertex Pharmaceuticals | 131.47 Bn | 123.62 Bn | 2.84 Bn | 32.99% |
| 4 | Regeneron Pharmaceuticals | 81.73 Bn | 73.74 Bn | 3.93 Bn | 30.23% |
| 5 | Argenx Se | 61.16 Bn | 55.98 Bn | 1.37 Bn | 31.16% |
| 6 | Moderna | 53.28 Bn | 48.14 Bn | 52.00 Mn | -539.31% |
| 7 | Alnylam Pharmaceuticals | 33.06 Bn | 29.76 Bn | 992.69 Mn | 12.74% |
| 8 | Biogen | 31.65 Bn | 30.37 Bn | 1.96 Bn | 3.56% |
| 9 | Roivant Sciences | 29.30 Bn | 29.30 Bn | 1.16 Mn | -20,152.98% |
| 10 | Insmed | 27.68 Bn | 26.52 Bn | 358.27 Mn | -3.12% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -134.51% |
| Mar 31, 2026 | 29.04% |
| Dec 31, 2025 | 31.90% |
| Sep 30, 2025 | 39.28% |
| Jun 30, 2025 | 27.69% |
| Mar 31, 2025 | 19.72% |
| Dec 31, 2024 | 23.54% |
| Sep 30, 2024 | 16.61% |
| Jun 30, 2024 | 23.22% |
| Mar 31, 2024 | -62.38% |
| Dec 31, 2023 | 19.90% |
| Sep 30, 2023 | 30.80% |
| Jun 30, 2023 | 15.74% |
| Mar 31, 2023 | 15.49% |
| Dec 31, 2022 | 22.10% |
| Sep 30, 2022 | 25.36% |
| Jun 30, 2022 | 18.13% |
| Mar 31, 2022 | 0.18% |
| Dec 31, 2021 | 5.19% |
| Sep 30, 2021 | 34.85% |